BBOX1 and chronic kidney disease: Given that these, and structurallyrelated, PHD inhibitors are typically prescribed for long-term useto treat CKD-associated anemia,52,103,104 the safety implications of off-target BBOX inhibition by PHD inhibitorsrequires further consideration.